Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Total Current Liabilities data on record, last reported at $85.1 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 42.54% year-over-year to $85.1 million; the TTM value through Dec 2025 reached $85.1 million, up 42.54%, while the annual FY2025 figure was $85.1 million, 42.54% up from the prior year.
  • Total Current Liabilities reached $85.1 million in Q4 2025 per CRNX's latest filing, up from $74.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $85.1 million in Q4 2025 and bottomed at $10.3 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $39.8 million, with a median of $36.5 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: fell 4.61% in 2021, then soared 119.1% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $16.0 million in 2021, then soared by 73.32% to $27.7 million in 2022, then skyrocketed by 58.5% to $43.9 million in 2023, then soared by 35.82% to $59.7 million in 2024, then skyrocketed by 42.54% to $85.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $85.1 million in Q4 2025, $74.2 million in Q3 2025, and $68.4 million in Q2 2025.